Kinase Chemistry – Just a year and a half behind the times.


Posted by kinasepro on October 3, 2006

Hi Novartis, nice follow on with WO2006101783. Here’s a representative example and their Markush:

Gleevec analog Markush



�Their latest application is a gleevec analog with a pyrrolopyrimidine hinge interaction, which looks nice enough. I wager they’re looking at a potency / selectivity angle. The added imidazo group probably brings in something like TIE2, or IKK… Think they could be a little more vague in your claims though?



>> Update. Ok, ok I guess there is more too it. I didn’t notice on the first pass but they claim to hit some Gleevec resistant strains. Good show.


3 Responses to “WO2006101783”

  1. otk said

    Interesting, they’ve actually published some simpler pyrollopyrimidines (Bioorg & Med Chem Letts (06) 2689), but they were follow-ons/me-too’s from some AstraZeneca work.

  2. Derek Lowe said

    Welcome! A person could write a full-time blog, albeit one for rather specialized tastes, doing nothing but mocking new kinase inhibitor patent applications. . .

  3. kinasepro said

    thanks for the BMCL hit

    As to ripping on patents? -> Could be fun.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: